BTG plc (LON:BTG) was upgraded by equities research analysts at Numis Securities Ltd to a “buy” rating in a report released on Monday. The firm currently has a GBX 900 ($11.14) target price on the stock. Numis Securities Ltd’s target price suggests a potential upside of 29.87% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Stifel Nicolaus downgraded BTG plc to a “hold” rating in a report on Thursday, July 14th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 790 ($9.78) price objective on shares of BTG plc in a report on Tuesday, August 16th. Finally, Deutsche Bank AG reiterated a “buy” rating on shares of BTG plc in a report on Thursday, September 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of GBX 822.86 ($10.18).

Analyst Recommendations for BTG plc (LON:BTG)

BTG plc (LON:BTG) opened at 689.00 on Monday. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 739.50. The stock has a 50 day moving average price of GBX 637.62 and a 200 day moving average price of GBX 643.12. The stock’s market capitalization is GBX 2.64 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other news, insider Soderstrom,Rolf sold 74,327 shares of the company’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.37), for a total transaction of £502,450.52 ($621,844.70).

About BTG plc

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with's FREE daily email newsletter.